IFM 2017-03: Phase III Trial of Daratumumab + Lenalidomide vs Lenalidomide + Dexamethasone in Frail Patients With Newly Diagnosed Multiple Myeloma

Source: Independent Conference Highlights of the 2022 ASH Annual Meeting*
Download Slideset
December 10-13, 2022; New Orleans, Louisiana
Among frail patients with newly diagnosed multiple myeloma, a dexamethasone-sparing regimen of daratumumab plus lenalidomide was associated with higher response rates and MRD negativity rates vs lenalidomide plus dexamethasone and had a favorable safety profile.
Format: Microsoft PowerPoint (.ppt)
File Size: 203 KB
Released: December 16, 2022

Acknowledgements

Provided by Clinical Care Options, LLC
Contact Info

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
AbbVie
AstraZeneca
Amgen
Epizyme
GSK
Incyte Corporation
Jazz Pharmaceuticals
Karyopharm Therapeutics Inc.
Novartis Pharmaceuticals Corporation
Sanofi
Seagen

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings